EN DE
STOCK COMPARISON

Merck & Company vs Swedish Orphan Biovitrum AB (publ): Fair Value & Quality

Both stocks run through our valuation models. Here is how Merck & Company (MRK) and Swedish Orphan Biovitrum AB (publ) (SOBI) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Merck & Company trades at $152 versus a fair value of $125 (-18%), while Swedish Orphan Biovitrum AB (publ) trades at SEK 455 versus SEK 214 (-53%).
Merck & Company
MRK · USD · Health Care
-18%
upside to fair value
overvalued
Price$152
Fair Value$125
Quality70/100
Swedish Orphan Biovitrum AB (publ)
SOBI.ST · SEK · Health Care
-53%
upside to fair value
overvalued
PriceSEK 455
Fair ValueSEK 214
Quality57/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Merck & CompanySwedish Orphan Biovitrum AB (publ)
Valuation
44.1×P/E (TTM)178.5×
4.64×P/S (TTM)5.65×
5.80×P/B4.34×
11.4×EV/EBITDA14.4×
6.10×PEG0.34×
−17.7%Fair value upside−53.0%
2.2%Dividend yield—
$3.28Dividend per share—
Profitability
39%Operating margin27%
2.70×EBIT margin trend (5Y)0.90×
19%Return on equity2%
13%Return on assets7%
Growth
5%Revenue growth (YoY)11%
3.1%Avg. growth/yr (3Y)14.5%
9.4%Avg. growth/yr (5Y)13.1%
+16.0%Value creation/yr−33.3%
Balance & size
17.3×Interest coverage (EBIT/interest)9.7×
0.89×Debt / equity0.14×
$305BMarket cap$17B
healthyGrowth qualitymixed

Merck & Company leads: 10 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Merck & Companyof which business quality 68 · market factors 90 Swedish Orphan Biovitrum AB (publ)of which business quality 60 · market factors 81
ProfitabilityMargins and returns on capital today
74
23
Quality GrowthAre margins and returns improving?
36
44
CashflowEarnings quality: real cash, not paper profit
65
100
Fin. StrengthBalance sheet, leverage, solvency risk
68
64
InvestmentDisciplined investing over empire-building
71
65
Low VolatilityCalm price path (market factor)
83
86
MomentumPrice trend over the last 3–12 months (market factor)
88
72
52W MomentumDistance to the 52-week high (market factor)
100
93
Net IssuanceBuybacks instead of dilution
91
60

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyMerck & CompanyPrice $152Swedish Orphan Biovitrum AB (publ)Price SEK 455
DCF Models-23%below the price$117+23%above the priceSEK 560
Earnings-Based-59%below the price$62.77-90%below the priceSEK 44.66
Dividend Discount-60%below the price$60.35n/a
Multiples-20%below the price$122-71%below the priceSEK 132
Asset-Based-91%below the price$14.27-84%below the priceSEK 73.07
Growth DCF-51%below the price$74.00+24%above the priceSEK 565
Economic Profit-45%below the price$83.85-54%below the priceSEK 211
Growth Earnings-9%close to the price$138-92%below the priceSEK 37.33
Minimum-91%below the price$14.27-92%below the priceSEK 37.33
Maximum-9%close to the price$138+24%above the priceSEK 565
Median-48%below the price$78.93-71%below the priceSEK 132
Geometric mean-53%below the price$71.25-69%below the priceSEK 140

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Merck & Company: 24 of 26 models see the stock below the current price.

Swedish Orphan Biovitrum AB (publ): 17 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Merck & Company
Bear $70.92Fair Value $125Bull $188
$152 = current price (white tick)
Swedish Orphan Biovitrum AB (publ)
Bear SEK 140Fair Value SEK 214Bull SEK 287
SEK 455 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Merck & Company · Health Care

Quality score70 · Top 25%
Fair value upside-18% · above median

Swedish Orphan Biovitrum AB (publ) · Health Care

Quality score57 · above median
Fair value upside-53% · below median

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees Merck & Company as the less overvalued of the two: Merck & Company trades at $152 versus a fair value of $125 (-18%), while Swedish Orphan Biovitrum AB (publ) trades at SEK 455 versus SEK 214 (-53%).

Merck & Company has the higher quality score (70/100).

See the full analysis →
Merck & Company · Swedish Orphan Biovitrum AB (publ)

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Merck & Company

Merck & Company vs UnitedHealth GroupEli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth Group

Related to Swedish Orphan Biovitrum AB (publ)

AstraZeneca vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAmgen vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.